ProQR Therapeutics is a clinical stage biopharmaceutical company. Co. is engaged in developing a pipeline of RNA therapies for inherited retinal diseases (IRD). Co. has treatments in various stages of preclinical discovery and development for different IRD causing mutations. This preclinical pipeline includes molecules for other mutations in Leber's congenital amaurosis, Usher syndrome, Stargardt's disease and other. Co. has discovered and developed a proprietary RNA editing platform technology called Axiomer®, which is designed to recruit endogenous Adenosine Deaminases Acting on RNA, enzymes to make single nucleotide changes in the RNA in a targeted manner at a desired location. The PRQR stock yearly return is shown above.
The yearly return on the PRQR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRQR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|